New Drug Futures (Musculoskeletal)
Products that could change the Pharma market to 2010 and beyond
| Price: £695.00 Approx $1,349.69 (USD) €1,038.06 (EUR) |
|
|---|---|
| Overview: | |
| This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the musculoskeletal sector. The report includes unique sales forecasts by major product. |
|
|
This paper is available from one of our partner sites.
Click here for details and to download it. |
|
By Dr CL Barton / Publication Date: 19th May 2006
Contents:
CURRENT MARKET SIZE 1
ANTI-RHEUMATIC DRUG SALES 3
ANTI-OSTEOPOROSIS DRUG SALES . 5
ADDRESSABLE PATIENT POPULATION 6
RHEUMATOID ARTHRITIS 6
OSTEOPOROSIS .6
CURRENT TREATMENTS 7
RHEUMATOID ARTHRITIS TREATMENTS .7
OSTEOPOROSIS TREATMENTS .8
RHEUMATOID ARTHRITIS SALES DRIVERS .9
OSTEOPOROSIS SALES DRIVERS .9
RHEUMATOID ARTHRITIS SALES BREAKERS .9
OSTEOPOROSIS SALES BREAKERS 10
FUTURE TREATMENTS .11
MARKET DYNAMICS - WINNERS & LOSERS .16
KEY DRUGS LAUNCHES BY 2010 17
KEY EVALUATION CRITERIA 18
KEY MUSCULOSKELETAL DRUG LAUNCHES BY 2010 .19
Actemra (Roche/Chugai) 19
Novelty/rationale for mechanism of action .19
Proof of concept/clinical data 19
Management/clinical expertise .20
Competition within the marketplace/gaining share of voice 20
Risks associated with developing a drug within a therapeutic class 20
Filings and approval .21
Sales forecasts and assumptions 21
Competitor Ratio Analysis .21
Bazedoxifene (Wyeth) 21
Novelty/rationale for mechanism of action 21
Proof of concept/clinical data .22
Management/clinical expertise .22
Competition within the marketplace/gaining share of voice 22
Risks associated with developing a drug within a therapeutic class 23
Filings and approval 23
Sales forecasts and assumptions .23
Competitor Ratio Analysis 23
Cimzia (UCB/Celltech) 24
Novelty/rationale for mechanism of action .24
Proof of concept/clinical data 24
Management/clinical expertise .25
Competition within the marketplace/gaining share of voice .25
Risks associated with developing a drug within a therapeutic class 25
Filings and approval 26
Sales forecasts and assumptions .26
Competitor Ratio Analysis 26
CNTO 148 (Johnson & Johnson/Schering-Plough) .27
Novelty/rationale for mechanism of action 27
Proof of concept/clinical data 27
Management/clinical expertise 27
Competition within the marketplace/gaining share of voice 28
Risks associated with developing a drug within a therapeutic class
Filings and approval .28
Sales forecasts and assumptions .28
Competitor Ratio Analysis .29
Denosumab (Amgen) .29
Novelty/rationale for mechanism of action 29
Proof of concept/clinical data .29
Management/clinical expertise .30
Competition within the marketplace/gaining share of voice 30
Risks associated with developing a drug within a therapeutic class .30
Filings and approval 30
Sales forecasts and assumptions .31
Competitor Ratio Analysis .31
Entereg (GlaxoSmithKline/Adolor) 31
Novelty/rationale for mechanism of action 31
Proof of concept/clinical data 31
Management/clinical expertise 32
Competition within the marketplace/gaining share of voice 32
Risks associated with developing a drug within a therapeutic class .32
Filings and approval .33
Sales forecasts and assumptions .33
Competitor Ratio Analysis 33
Febuxostat (TAP Pharmaceutical Products) 34
Novelty/rationale for mechanism of action.34
Proof of concept/clinical data 34
Management/clinical expertise .34
Competition within the marketplace/gaining share of voice 34
Risks associated with developing a drug within a therapeutic class 34
Filings and approval .34
Sales forecasts and assumptions 35
Competitor Ratio Analysis .35
Orencia (Bristol-Myers Squibb) .35
Novelty/rationale for mechanism of action .35
Proof of concept/clinical data 35
Management/clinical expertise 36
Competition within the marketplace/gaining share of voice 36
Sales forecasts and assumptions .37
Competitor Ratio Analysis .38
Preos (NPS Pharmaceuticals) 38
Novelty/rationale for mechanism of action 38
Proof of concept/clinical data .38
POWER Study .39
PaTH Study .39
Management/clinical expertise .39
Competition within the marketplace/gaining share of voice 39
Filings and approval 40
Sales forecasts and assumptions .40
Competitor Ratio Analysis .40
COMPETITOR RATIO ANALYSIS SUMMARY . 41
COMPETITOR RATIO ANALYSIS - COMPANIES 44